Position in IDYA
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$4,387,163
New position
Shares Held
117,713
first reported quarter
Ownership
0.122%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#79
of 286 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 88%
Shared 0%
None 12%
Position in Biotechnology
Healthcare · as of Jun 30, 2026CONGRESS ASSET MANAGEMENT CO holds $715,705,658 across 14 Biotechnology names. IDYA ranks #11 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
659,911 | $208,591,267 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
2,600,123 | $142,850,757 | |
| 3 | VCEL |
Vericel Corp
|
2,916,295 | $129,745,964 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
1,229,106 | $96,202,126 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
265,701 | $79,983,972 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
40,134 | $14,916,603 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
380,746 | $11,902,119 | |
| 8 | RLAY |
Relay Therapeutics, Inc.
|
626,141 | $11,715,098 |
All Filings in IDYA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,387,163 | 117,713 | Shares | Sole | 2026-07-07 | |
| No filing history on record for this holder in this stock. | ||||||